-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – UBX-1325 in Diabetic Retinopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - UBX-1325 in Diabetic Retinopathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. UBX-1325 in Diabetic Retinopathy Drug Details: UBX-1325 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – UBX-1325 in Diabetic Macular Edema
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - UBX-1325 in Diabetic Macular Edema report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. UBX-1325 in Diabetic Macular Edema Drug Details: UBX-1325 is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Typhella in Typhoid Fever
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Typhella in Typhoid Fever report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Typhella in Typhoid Fever Drug Details: Typhella is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Axicabtagene Ciloleucel in Burkitt Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Axicabtagene Ciloleucel in Burkitt Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Axicabtagene Ciloleucel in Burkitt Lymphoma Drug Details: Axicabtagene ciloleucel (KTE-C19...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vudalimab in Neuroendocrine Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vudalimab in Neuroendocrine Carcinoma Drug Details: XmAb-717 is under development for the treatment of cervical...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MP-0310 in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MP-0310 in Non-Small Cell Lung Cancer Drug Details: MP-0310 is under development for the treatment...
-
Product Insights
NewNet Present Value Model: Unity Biotechnology Inc’s UBX-1325
Empower your strategies with our Net Present Value Model: Unity Biotechnology Inc's UBX-1325 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sitravatinib Malate in Well Differentiated Liposarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Sitravatinib Malate in Well Differentiated Liposarcoma Drug Details: Sitravatinib malate is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HL-5101 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HL-5101 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.HL-5101 in Non-Small Cell Lung Cancer Drug Details:HL-5101 (NOV-1601) is under...